Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B

Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

BMS and Celgene deal sparks debate on pharma profit motive, more M&A Meanwhile Merck &Co has had enormous success with its immuno-oncology market leader Keytruda, but the rest of its portfolio is looking distinctly threadbare by comparison, with some investors eager for

BMS and Celgene announce $74bn merger

BMS and Celgene announce $74bn merger BMS and Celgene have each had their travails in recent times: BMS has seen its first-to-market immunotherapy Opdivo overtaken by Merck &Co’s rival Keytruda, while Celgene suffered numerous

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year in the body where the tumour originated (after Merck &Co’s Keytruda), and GW Pharma’s epilepsy therapy Epidiolex (cannabidiol) which is the first FDA-approved drug based on cannabis.

Is China ready for a pharmaceutical gold rush?

Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in lung cancer.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics